La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Trevena Croissance future

Future contrôle des critères 0/6

Les revenus et les bénéfices de Trevena devraient diminuer respectivement de 2.8% et de 1.5% par an, tandis que le BPA devrait croître de croître de 20.1% par an.

Informations clés

-1.5%

Taux de croissance des bénéfices

20.1%

Taux de croissance du BPA

Biotechs croissance des bénéfices	28.5%
Taux de croissance des recettes	-2.8%
Rendement futur des capitaux propres	n/a
Couverture par les analystes	Low
Dernière mise à jour	09 Aug 2024

Mises à jour récentes de la croissance future

Recent updates

Prévisions de croissance des bénéfices et des revenus

NasdaqCM:TRVN - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	N/A	-32	N/A	N/A	1
12/31/2025	9	-21	N/A	N/A	2
12/31/2024	0	-26	N/A	N/A	1
6/30/2024	0	-37	-32	-32	N/A
3/31/2024	3	-40	-32	-32	N/A
12/31/2023	3	-40	-33	-33	N/A
9/30/2023	3	-31	-38	-38	N/A
6/30/2023	3	-38	-39	-39	N/A
3/31/2023	0	-45	-44	-44	N/A
12/31/2022	0	-54	-52	-51	N/A
9/30/2022	0	-61	-53	-53	N/A
6/30/2022	0	-59	-54	-54	N/A
3/31/2022	0	-58	-54	-54	N/A
12/31/2021	1	-52	-50	-50	N/A
9/30/2021	1	-50	-45	-45	N/A
6/30/2021	3	-41	-36	-36	N/A
3/31/2021	3	-33	-30	-30	N/A
12/31/2020	3	-29	-21	-21	N/A
9/30/2020	3	-24	-21	-21	N/A
6/30/2020	0	-27	-25	-25	N/A
3/31/2020	0	-25	-22	-22	N/A
12/31/2019	0	-25	-24	-24	N/A
9/30/2019	0	-26	-22	-23	N/A
6/30/2019	3	-22	-20	-20	N/A
3/31/2019	6	-27	-23	-23	N/A
12/31/2018	6	-31	-26	-25	N/A
9/30/2018	6	-38	-32	-31	N/A
6/30/2018	3	-49	-41	-39	N/A
3/31/2018	N/A	-60	N/A	-52	N/A
12/31/2017	N/A	-72	N/A	-71	N/A
9/30/2017	N/A	-93	N/A	-87	N/A
6/30/2017	N/A	-107	N/A	-100	N/A
3/31/2017	2	-106	N/A	-100	N/A
12/31/2016	4	-103	N/A	-92	N/A
9/30/2016	6	-82	N/A	-76	N/A
6/30/2016	8	-63	N/A	-63	N/A
3/31/2016	8	-55	N/A	-55	N/A
12/31/2015	6	-51	N/A	-40	N/A
9/30/2015	4	-48	N/A	-41	N/A
6/30/2015	3	-53	N/A	-40	N/A
3/31/2015	1	-53	N/A	-40	N/A
12/31/2014	N/A	-50	N/A	-40	N/A
9/30/2014	N/A	-43	N/A	-37	N/A
6/30/2014	N/A	-37	N/A	-33	N/A
3/31/2014	0	-30	N/A	-28	N/A
12/31/2013	0	-24	N/A	-24	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: TRVN devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: TRVN devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: TRVN devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Les revenus de TRVN devraient diminuer au cours des 3 prochaines années ( -2.8% par an).

Croissance élevée des revenus: Les revenus de TRVN devraient diminuer au cours des 3 prochaines années ( -2.8% par an).

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de TRVN devrait être élevé dans 3 ans

Trevena Croissance future

Future contrôle des critères 0/6

Informations clés

Mises à jour récentes de la croissance future

No longer forecast to breakeven

Consensus EPS estimates fall by 28%, revenue upgraded

Consensus revenue estimates increase by 725%

Price target decreased by 39% to US$17.00

Price target decreased to US$28.67

Consensus forecasts updated

Recent updates

Trevena Regains Compliance with the Minimum Bid Price Requirement from Nasdaq

New major risk - Share price stability

New major risk - Revenue and earnings growth

Second quarter 2024 earnings released: US$0.23 loss per share (vs US$0.69 loss in 2Q 2023)

Trevena, Inc. Announces Preclinical TRV045 Data Providing Insight Into Novel Mechanism of Analgesic Effect in Chronic Neuropathic Pain Model and Demonstrating Statistically Significant Anti-Seizure Activity in Epilepsy Models

First quarter 2024 earnings released: US$0.36 loss per share (vs US$0.81 loss in 1Q 2023)

Nasdaq Hearings Panel Grants Trevena an Extension Until August 28, 2024 to Regain Compliance with the Nasdaq Continued Listing Requirements, Including the Minimum Bid Price Requirement and Equity Standard Requirement

Trevena, Inc., Annual General Meeting, Jun 13, 2024

New major risk - Revenue and earnings growth

Full year 2023 earnings: EPS and revenues miss analyst expectations

No longer forecast to breakeven

New major risk - Market cap size

Trevena, Inc. Promotion of Barry Shin to the Position of Executive Vice President and Chief Operating Officer

Trevena, Inc. announced that it expects to receive $1.945934 million in funding

Trevena, Inc. announced that it expects to receive $1.945934 million in funding

Trevena, Inc. announced that it expects to receive $1.945934 million in funding

Trevena, Inc. Announces Acceptance of Abstract Examining the Use of Olinvyk in Patients with Acute Burn Injuries

New major risk - Revenue and earnings growth

Consensus EPS estimates fall by 28%, revenue upgraded

Trevena, Inc. Announces Board Changes

Trevena, Inc. to Report Q3, 2023 Results on Nov 14, 2023

New major risk - Revenue and earnings growth

Trevena, Inc. Announces Completion of Initial Analysis of Olinvyk Continuous Respiratory Monitoring Data from Volition Study

Trevena, Inc. Announces Retirement of Michael Dougherty as A Member of the Board of Directors and as A Member of the Audit Committee, Effective as of September 14, 2023

Trevena, Inc. Announces Preliminary TRV045 Data from Two Proof-Of-Concept Studies Evaluating S1pr Mechanism of Action and CNS Target Engagement

Trevena Receives Non-Compliance Notice From Nasdaq Stock Market

Consensus revenue estimates increase by 725%

New major risk - Market cap size

Trevena, Inc. Appoints Mark Corrigan to Board of Directors

Trevena, Inc. Announces New Topline OLINVYK Data Highlighting Reduced Cost Per Admission from Artemis Real-World Outcomes Study

New major risk - Market cap size

Trevena Regains Compliance with the Minimum Bid Price Requirement under Nasdaq Listing Rule 5550(a)(2)

Trevena, Inc. to Report Q1, 2023 Results on May 15, 2023

Price target decreased by 39% to US$17.00

Trevena Announces Publication of OLINVYK Respiratory Physiology Study in ANESTHESIOLOGY

Trevena, Inc. Enrolls First Subject in TRV045 Proof-of-Concept Trial Evaluating S1PR Mechanism of Action and Target Engagement

Trevena Regains Compliance with Nasdaq Listing Requirements

Price target decreased to US$28.67

Insufficient new directors

Trevena Announces Completion of Phase 1 Study for Trv045, Novel S1p Receptor Modulator

Trevena, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Trevena Announces OLINVYK Poster Presentation at the ANESTHESIOLOGY® 2022 Annual Meeting

Consensus forecasts updated

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Trevena Q2 2022 Earnings Preview

Trevena, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Trevena Announces Positive Topline OLINVYK Cognitive Function Data and Provides General Business Update

Trevena slides on $2M preferred stock offering

Trevena (NASDAQ:TRVN) Will Have To Spend Its Cash Wisely

Trevena Gets an Additional 180 Days to Get Listing Compliance

Consensus revenue estimates fall by 36%

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Trevena, Inc., Annual General Meeting, Jun 09, 2022

Insufficient new directors

Trevena, Inc. Receives Notice to Cease Enrollment for TRV027 as Part of the ACTIV-4 Host Tissue Platform

Trevena, Inc. Announces Results from Pfound D Sedation, Respiratory Depression, Coma, and Death May Result from E Concomitant Use of Olinvyk

Consensus forecasts updated

Trevena, Inc. to Report Q4, 2021 Results on Mar 31, 2022

Is Trevena (NASDAQ:TRVN) In A Good Position To Deliver On Growth Plans?

Price target decreased to US$4.67

Insufficient new directors

Trevena, Inc. Announces Submission of New Drug Application in China for OLINVYK® by its Partner Jiangsu Nhwa Pharmaceutical

Trevena, Inc. Announces Advancement of TRV045 Into Clinical Development for Diabetic Neuropathic Pain

Trevena Offers An Enticing Risk-Reward At These Prices

Trevena Announces Wake Forest Baptist Health Joining OLINVYK® Clinical Outcomes Study

Trevena: Remaining Patient After A Disappointing Q2 Earnings

Trevena Announces Publication of OLINVYK® Health Economic Model in Journal of Comparative Effectiveness Research

Trevena Announces NIH Has Resumed Recruiting Patients in Proof-of-Concept Study for TRV734 in Opioid Use Disorder

Trevena announces resumption of NIH-run trial for TRV734 in opioid use disorder